FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366602942> ?p ?o ?g. }

• W4366602942 endingPage "12451" @default.
• W4366602942 startingPage "12438" @default.
• W4366602942 abstract "TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53's DNA binding domain. The aim of this study was to explain the reason why R175H worse the response to immunotherapy by analyzing tumor immune microenvironment through the expression of immune cells and PD-1.Patients diagnosed with metastatic carcinoma, including colorectal cancer (CRC), breast cancer (BRCA), gastric cancer (GC), non-small cell lung cancer (NSCLC), and 20 other cancer types, treated in a palliative setting at Samsung Medical Center between October 2019 and April 2021, were enrolled. Of these patients, those who underwent TDS analysis (TruSight™ Oncology 500 assay [TSO 500]) were finally analyzed.Of 1770 patients, 1012 (57.2%) harbored genetic alterations in TP53. All mutations were single nucleotide variants (SNVs), and the most frequent SNV was R175H (n = 84, 7.5%) which was known as one of the most common hotspot TP53 mutation. The overall survival of patients with TP53 R175H mutations was significantly worse following chemotherapy (606 vs. 456 days, p < 0.001) or immunotherapy (822 vs. 350 days, p < 0.001) compared to those with TP53 mutation in other loci. RNA sequencing indicated that the immune response-related pathways were downregulated in tumors harboring TP53 R175H mutation. Moreover, the expression of CD8(+) T cells PD-1 were lowered in R175H mutation tumors. In the analysis of TP53 structural domain, compared to those having TP53 mutation in other domain, patients with mutations occurring in the nuclear exporter signal (NES) and E4F1-binding domains had significantly worse overall survival following chemotherapy (NES: 606 vs. 451 days, p = 0.043; E4F1: 606 vs. 469 days, p = 0.046) and immunotherapy (NES: 822 vs. 403 days, p < 0.001; E4F1: 822 vs. 413 days, p < 0.001). In addition, tumors with TP53 mutation and co-existing copy number amplification of CCND1, FGF4, and FGF19 in chromosome 11 conferred worse prognosis than those with only TP53 mutation (p < 0.050).Each TP53 mutations indicated differential treatment outcomes following chemotherapy or immunotherapy in patients with metastatic cancer. Functional analysis including RNASeq suggested that TP53 mutation downregulated immune response.Overall, we found each TP53 mutation to indicate different prognoses in patients with metastatic tumors undergoing chemotherapy and ICI treatment. Further validations, including a prospective cohort study or a functional study, would be particularly valuable in advancing the knowledge on this aspect and developing improved prognostic parameters." @default.
• W4366602942 created "2023-04-23" @default.
• W4366602942 creator A5013175108 @default.
• W4366602942 creator A5019406140 @default.
• W4366602942 creator A5055431215 @default.
• W4366602942 creator A5073628731 @default.
• W4366602942 creator A5089465499 @default.
• W4366602942 date "2023-04-20" @default.
• W4366602942 modified "2023-10-05" @default.
• W4366602942 title "<scp><i>TP53</i></scp> mutations predict poor response to immunotherapy in patients with metastatic solid tumors" @default.
• W4366602942 cites W1538390196 @default.
• W4366602942 cites W1968075505 @default.
• W4366602942 cites W1977415453 @default.
• W4366602942 cites W1980472836 @default.
• W4366602942 cites W1980740976 @default.
• W4366602942 cites W1980810506 @default.
• W4366602942 cites W1982259691 @default.
• W4366602942 cites W1985271346 @default.
• W4366602942 cites W1995068068 @default.
• W4366602942 cites W1998287298 @default.
• W4366602942 cites W1999574084 @default.
• W4366602942 cites W2002376765 @default.
• W4366602942 cites W2004944197 @default.
• W4366602942 cites W2014850113 @default.
• W4366602942 cites W2024405748 @default.
• W4366602942 cites W2028885314 @default.
• W4366602942 cites W2032076692 @default.
• W4366602942 cites W2043912950 @default.
• W4366602942 cites W2064795157 @default.
• W4366602942 cites W2081411230 @default.
• W4366602942 cites W2084831115 @default.
• W4366602942 cites W2096849855 @default.
• W4366602942 cites W2098833890 @default.
• W4366602942 cites W2114023704 @default.
• W4366602942 cites W2114261502 @default.
• W4366602942 cites W2163565167 @default.
• W4366602942 cites W2169456326 @default.
• W4366602942 cites W2169908872 @default.
• W4366602942 cites W2262414037 @default.
• W4366602942 cites W2275877493 @default.
• W4366602942 cites W2285093314 @default.
• W4366602942 cites W2765694924 @default.
• W4366602942 cites W2796153225 @default.
• W4366602942 cites W2886372396 @default.
• W4366602942 cites W3045935025 @default.
• W4366602942 cites W3134236823 @default.
• W4366602942 cites W3177731577 @default.
• W4366602942 cites W4280559744 @default.
• W4366602942 cites W4366602942 @default.
• W4366602942 doi "https://doi.org/10.1002/cam4.5953" @default.
• W4366602942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37081749" @default.
• W4366602942 hasPublicationYear "2023" @default.
• W4366602942 type Work @default.
• W4366602942 citedByCount "1" @default.
• W4366602942 countsByYear W43666029422023 @default.
• W4366602942 crossrefType "journal-article" @default.
• W4366602942 hasAuthorship W4366602942A5013175108 @default.
• W4366602942 hasAuthorship W4366602942A5019406140 @default.
• W4366602942 hasAuthorship W4366602942A5055431215 @default.
• W4366602942 hasAuthorship W4366602942A5073628731 @default.
• W4366602942 hasAuthorship W4366602942A5089465499 @default.
• W4366602942 hasBestOaLocation W43666029421 @default.
• W4366602942 hasConcept C104317684 @default.
• W4366602942 hasConcept C121608353 @default.
• W4366602942 hasConcept C126322002 @default.
• W4366602942 hasConcept C141231307 @default.
• W4366602942 hasConcept C153911025 @default.
• W4366602942 hasConcept C203014093 @default.
• W4366602942 hasConcept C2776162770 @default.
• W4366602942 hasConcept C2776256026 @default.
• W4366602942 hasConcept C2777701055 @default.
• W4366602942 hasConcept C2781230642 @default.
• W4366602942 hasConcept C501734568 @default.
• W4366602942 hasConcept C502942594 @default.
• W4366602942 hasConcept C526805850 @default.
• W4366602942 hasConcept C54355233 @default.
• W4366602942 hasConcept C71924100 @default.
• W4366602942 hasConcept C86803240 @default.
• W4366602942 hasConcept C8891405 @default.
• W4366602942 hasConceptScore W4366602942C104317684 @default.
• W4366602942 hasConceptScore W4366602942C121608353 @default.
• W4366602942 hasConceptScore W4366602942C126322002 @default.
• W4366602942 hasConceptScore W4366602942C141231307 @default.
• W4366602942 hasConceptScore W4366602942C153911025 @default.
• W4366602942 hasConceptScore W4366602942C203014093 @default.
• W4366602942 hasConceptScore W4366602942C2776162770 @default.
• W4366602942 hasConceptScore W4366602942C2776256026 @default.
• W4366602942 hasConceptScore W4366602942C2777701055 @default.
• W4366602942 hasConceptScore W4366602942C2781230642 @default.
• W4366602942 hasConceptScore W4366602942C501734568 @default.
• W4366602942 hasConceptScore W4366602942C502942594 @default.
• W4366602942 hasConceptScore W4366602942C526805850 @default.
• W4366602942 hasConceptScore W4366602942C54355233 @default.
• W4366602942 hasConceptScore W4366602942C71924100 @default.
• W4366602942 hasConceptScore W4366602942C86803240 @default.
• W4366602942 hasConceptScore W4366602942C8891405 @default.
• W4366602942 hasFunder F4320322107 @default.
• W4366602942 hasFunder F4320322120 @default.

• next